comparemela.com

Bernard Courtieu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IntegraGen: Annual Results 2023 - Positive EBITDA Reflecting Tight Cost Control

Increase in services provided in 2023 by all sequencing platforms, excluding COVID-related activities Positive EBITDA for the third year running, despite inflation impacting reagent.

France generalUnited statesUnited kingdomInstitut pasteurBernard courtieuCollege of american pathologistsClinical laboratory improvement amendmentsRegulatory newsAmerican pathologistsMutualized microbiology platformQuality assuranceState guaranteed loanEuronext growth

IntegraGen Reports €11 8M Revenues for 2023

IntegraGen Reports €11 8M Revenues for 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalUnited kingdomUnited statesVirginie decosterInstitut pasteurBernard courtieuOncodna groupCollege of american pathologistsAmerican pathologistsEuronext growth

IntegraGen Reports €5 6m in Revenues for H1 2023 Representing 13% Decrease Compared to H1 2022 and a Cash Position of €4 3m

IntegraGen Reports €5 6m in Revenues for H1 2023 Representing 13% Decrease Compared to H1 2022 and a Cash Position of €4 3m
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomFrance generalBernard courtieuBelgian oncodna groupOncodna groupEuronext growthDie experten

IntegraGen : reports 2022 annual results with a growth of 16% in revenues and a positive EBITDA

Increase of activities performed on all sequencing platforms Positive EBITDA for the second consecutive year despite inflation impact on reagents . | April 24, 2023

United kingdomFrance generalInstitut pasteurGustave roussyInstitut curieBernard courtieuEuropean society of medical oncologyOncodna groupEuropean societyMedical oncologyAssistance publique hEuronext growthIntegragen stock exchangePress releaseN alint fr0010908723

IntegraGen Reports €12 6m in Revenues for 2022 Representing 16% Growth Compared to 2021 and a Cash Position of €4 5m

Growth supported by the high-throughput genomic sequencing laboratory in Evry Continued sequencing activities on platforms operated on behalf of third parties supported by new clinical research

France generalUnited kingdomBernard courtieuOncodna groupEuronext growthMedia relations

vimarsana © 2020. All Rights Reserved.